C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	78.16	55.5	126.59	29.75	76.12	181.73
Short-Term Investments	136.4	189.41	127.09	246.4	233.16	189.96
Cash & Short-Term Investments	214.55	244.9	253.68	276.15	309.28	371.69
Cash Growth	-18.76%	-3.46%	-8.14%	-10.71%	-16.79%	310.48%
Receivables	2.16	3.1	11.8	1.47	5.72	4.48
Prepaid Expenses	8.02	9.76	5.71	9.93	10.69	4.84
Total Current Assets	224.73	257.77	271.19	287.56	325.69	381.01
Property, Plant & Equipment	59.76	63.38	71.09	77.52	35.05	16.55
Long-Term Investments	8.42	22.36	28.01	60.96	142.2	-
Other Long-Term Assets	3.62	6.1	6.17	4.81	3.82	2.58
Total Assets	296.53	349.6	376.45	430.84	506.77	400.14
Accounts Payable	2.22	1.33	1.45	1.17	4.51	5.68
Accrued Expenses	11.98	17.49	15.49	16.66	13.19	9.06
Current Portion of Long-Term Debt	-	-	-	2.29	-	-
Current Portion of Leases	6.07	5.77	5.22	4.7	1.33	1.04
Current Unearned Revenue	22.62	18.71	15.47	16.62	31.8	27.6
Other Current Liabilities	1.58	1.87	5.14	3.11	0.41	0.47
Total Current Liabilities	44.46	45.18	42.77	44.55	51.25	43.85
Long-Term Debt	-	-	-	9.2	10.77	10.05
Long-Term Leases	56.86	59.98	65.76	70.97	30.78	11.83
Long-Term Unearned Revenue	21.15	28.46	21.81	16.9	24.37	53.62
Total Liabilities	122.46	133.62	130.34	141.61	117.16	119.35
Common Stock	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-In Capital	860.13	849.63	774.62	689.26	658.09	464.6
Retained Earnings	-686.04	-633.7	-528.38	-395.89	-267.72	-183.82
Comprehensive Income & Other	-0.03	0.05	-0.13	-4.14	-0.78	0.01
Total Common Equity	174.06	215.99	246.11	289.23	389.61	280.79
Shareholders' Equity	174.06	215.99	246.11	289.23	389.61	280.79
Total Liabilities & Equity	296.53	349.6	376.45	430.84	506.77	400.14
Total Debt	62.92	65.76	70.98	87.15	42.88	22.92
Net Cash (Debt)	160.05	201.51	210.71	249.96	408.6	348.77
Net Cash Growth	-29.59%	-4.37%	-15.70%	-38.82%	17.16%	354.13%
Net Cash Per Share	2.27	2.90	4.24	5.12	8.87	30.67
Filing Date Shares Outstanding	71.17	70.99	68.6	49.05	48.74	43.12
Total Common Shares Outstanding	71.01	70.63	60.47	48.97	48.69	43.06
Working Capital	180.27	212.59	228.42	243.01	274.44	337.16
Book Value Per Share	2.45	3.06	4.07	5.91	8.00	6.52
Tangible Book Value	174.06	215.99	246.11	289.23	389.61	280.79
Tangible Book Value Per Share	2.45	3.06	4.07	5.91	8.00	6.52
Machinery	10.85	10.37	10.18	10.66	9.48	8.41
Construction In Progress	-	-	-	0.18	-	-
Leasehold Improvements	4.71	4.71	4.71	4.68	0.54	0.54

Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q